| Literature DB >> 34071296 |
Valentina Monistero1, Antonio Barberio2, Paola Cremonesi3, Bianca Castiglioni3, Stefano Morandi4, Desiree C K Lassen5, Lærke B Astrup5, Clara Locatelli1, Renata Piccinini1, M Filippa Addis1, Valerio Bronzo1, Paolo Moroni1,6.
Abstract
Streptococcus uberis, an environmental pathogen responsible also for contagious transmission, has been increasingly implicated in clinical mastitis (CM) cases in Europe. We described a 4-month epidemiological investigation of Strep. uberis CM cases in an Italian dairy farm. We determined molecular characteristics and phenotypic antimicrobial resistance of 71 Strep. uberis isolates from dairy cows with CM. Genotypic variability was investigated via multiplex PCR of housekeeping and virulence genes, and by RAPD-PCR typing. Antimicrobial susceptibility was assessed for 14 antimicrobials by MIC assay. All the isolates carried the 11 genes investigated. At 90% similarity, two distinct clusters, grouping 69 of the 71 isolates, were detected in the dendrogram derived from the primer ERIC1. The predominant cluster I could be separated into two subclusters, containing 38 and 14 isolates, respectively. Strep. uberis strains belonging to the same RAPD pattern differed in their resistance profiles. Most (97.2%) of them were resistant to at least one of the drugs tested, but only 25.4% showed a multidrug resistance phenotype. The highest resistance rate was observed for lincomycin (93%), followed by tetracycline (85.9%). This study confirmed a low prevalence of β-lactam resistance in Strep. uberis, with only one isolate showing resistance to six antimicrobial classes, including cephalosporins.Entities:
Keywords: MIC; RAPD; Streptococcus uberis; clinical mastitis; cow
Year: 2021 PMID: 34071296 PMCID: PMC8229259 DOI: 10.3390/antibiotics10060644
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Unweighted pair group method with arithmetic averages (UPGMA)-based dendrogram derived from the RAPD-PCR profiles generated with primer ERIC1 of the 71 Strep. uberis strains isolated from 71 quarters of different cows.
Antimicrobials tested, dilution range, breakpoints values, percentage of susceptible, intermediate and resistant Strep. uberis isolates, MIC inhibiting the growth of at least 50% (MIC50) and 90%(MIC90) of the 71 isolates analyzed.
| Antimicrobials | Range (µg/mL) | Breakpoints (µg/mL) and Susceptibility | MIC50
| MIC90
| Reference | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| S 1 | [%] | I 2 | [%] | R 3 | [%] | |||||
| AMC 4 | 0.064/0.032–64/32 | ≤0.25/0.125 | 98.6 | 0.5/0.25 | 0 | >1/0.5 | 1.4 | 0.25/0.125 | 0.25/0.125 | [ |
| AMP 5 | 0.016–16 | ≤0.25 | 98.6 | 0.5 | 0 | >2 | 1.4 | 0.25 | 0.25 | [ |
| CEZ 6 | 0.125–32 | ≤2 | 98.6 | 4 | 0 | >8 | 1.4 | 0.5 | 0.5 | [ |
| CPZ 7 | 0.125–16 | ≤2 | 97.2 | 4 | 1.4 | >8 | 1.4 | 1 | 2 | [ |
| CEQ 8 | 0.125–8 | ≤2 | 98.6 | >4 | 1.4 | ≤0.125 | 0.25 | [ | ||
| CEF 9 | 0.125–32 | ≤2 | 98.6 | 4 | 0 | >8 | 1.4 | 0.5 | 1 | [ |
| ENRO 10 | 0.016–8 | ≤0.5 | 91.6 | 1–2 | 7 | >4 | 1.4 | 0.5 | 0.5 | [ |
| ERY 11 | 0.125–8 | ≤0.25 | 91.6 | 0.5 | 2.8 | >1 | 5.6 | ≤0.125 | ≤0.125 | [ |
| FLL 12 | 0.064–64 | ≤2 | 94.4 | 4 | 5.6 | >8 | 0 | 2 | 2 | [ |
| LIN 13 | 1–8 | ≤2 | 7 | 4–8 | 11.3 | >18 | 81.7 | >8 | >8 | [ |
| OXA 14 | 0.125–4 | ≤2 | 95.8 | >4 | 4.2 | 2 | 2 | [ | ||
| PEN 15 | 0.0625–16 | ≤0.125 | 84.5 | 0.25–2 | 12.7 | >4 | 2.8 | 0.125 | 0.25 | [ |
| TET 16 | 0.032–16 | ≤2 | 14.1 | 4 | 2.8 | >8 | 83.1 | >16 | >16 | [ |
| T/S 17 | 0.016/0.304–32/608 | ≤1/19 | 98.6 | >2/38 | 1.4 | 0.062/1.18 | 0.125/2.37 | [ | ||
1 Susceptible, 2 Intermediate, 3 Resistant, 4 Amoxicillin/clavulanic acid, 5 Ampicillin, 6 Cefazolin, 7 Cefoperazone, 8 Cefquinome, 9 Ceftiofur, 10 Enrofloxacin, 11 Erythromycin, 12 Florfenicol, 13 Lincomycin, 14 Oxacillin, 15 Penicillin, 16 Tetracycline, 17 Trimethoprim/sulfamethoxazole.
Distribution of the MIC50 and MIC90 for the 14 antimicrobial agents between the genotypic clusters, and cumulative percentage of Strep. uberis strains inhibited by their relative concentrations.
| Antimicrobial | Cluster I | Cluster II | ||||||
|---|---|---|---|---|---|---|---|---|
| MIC50 | MIC90 | MIC50 | MIC90 | |||||
| (μg/mL) | [%] | (μg/mL) | [%] | (μg/mL) | [%] | (μg/mL) | [%] | |
| AMC 1 | 0.25/0.125 | 98 | 0.25/0.125 | 98 | 0.125/0.064 | 53 | 0.25/0.125 | 100 |
| AMP 2 | 0.25 | 98 | 0.25 | 98 | 0.125 | 53 | 0.25 | 100 |
| CEZ 3 | 0.5 | 92 | 0.5 | 92 | 0.5 | 88 | 1 | 100 |
| CPZ 4 | 1 | 73 | 2 | 96 | 1 | 65 | 2 | 100 |
| CEQ 5 | 0.25 | 96 | 0.25 | 96 | ≤0.125 | 71 | 0.25 | 94 |
| CEF 6 | 0.5 | 69 | 1 | 96 | 0.5 | 94 | 0.5 | 94 |
| ENRO 7 | 0.5 | 88 | 1 | 94 | 0.5 | 100 | 0.5 | 100 |
| ERY 8 | ≤0.125 | 90 | ≤0.125 | 90 | ≤0.125 | 94 | ≤0.125 | 94 |
| FLL 9 | 2 | 94 | 2 | 94 | 2 | 94 | 2 | 94 |
| LIN 10 | >8 | 100 | >8 | 100 | >8 | 100 | >8 | 100 |
| OXA 11 | 2 | 96 | 2 | 96 | 2 | 94 | 2 | 94 |
| PEN 12 | 0.125 | 81 | 0.25 | 96 | 0.125 | 94 | 0.125 | 94 |
| TET 13 | >16 | 100 | >16 | 100 | >16 | 100 | >16 | 100 |
| T/S 14 | 0.062/1.18 | 83 | 0.125/2.37 | 96 | 0.062/1.18 | 94 | 0.062/1.18 | 94 |
1 Amoxicillin/clavulanic acid, 2 Ampicillin, 3 Cefazolin, 4 Cefoperazone, 5 Cefquinome., 6 Ceftiofur, 7 Enrofloxacin, 8 Erythromycin, 9 Florfenicol, 10 Lincomycin, 11 Oxacillin, 12 Penicillin, 13 Tetracycline, 14 Trimethoprim/sulfamethoxazole.